Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database
Top Cited Papers
Open Access
- 11 July 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 131 (9), 2443-2454
- https://doi.org/10.1093/brain/awn146
Abstract
Ventricular enlargement may be an objective and sensitive measure of neuropathological change associated with mild cognitive impairment (MCI) and Alzheimer's disease (AD), suitable to assess disease progression for multi-centre studies. This study compared (i) ventricular enlargement after six months in subjects with MCI, AD and normal elderly controls (NEC) in a multi-centre study, (ii) volumetric and cognitive changes between Apolipoprotein E genotypes, (iii) ventricular enlargement in subjects who progressed from MCI to AD, and (iv) sample sizes for multi-centre MCI and AD studies based on measures of ventricular enlargement. Three dimensional T1-weighted MRI and cognitive measures were acquired from 504 subjects (NEC n = 152, MCI n = 247 and AD n = 105) participating in the multi-centre Alzheimer's Disease Neuroimaging Initiative. Cerebral ventricular volume was quantified at baseline and after six months using semi-automated software. For the primary analysis of ventricle and neurocognitive measures, between group differences were evaluated using an analysis of covariance, and repeated measures t-tests were used for within group comparisons. For secondary analyses, all groups were dichotomized for Apolipoprotein E genotype based on the presence of an ε4 polymorphism. In addition, the MCI group was dichotomized into those individuals who progressed to a clinical diagnosis of AD, and those subjects that remained stable with MCI after six months. Group differences on neurocognitive and ventricle measures were evaluated by independent t-tests. General sample size calculations were computed for all groups derived from ventricle measurements and neurocognitive scores. The AD group had greater ventricular enlargement compared to both subjects with MCI (P = 0.0004) and NEC (P< 0.0001), and subjects with MCI had a greater rate of ventricular enlargement compared to NEC (P = 0.0001). MCI subjects that progressed to clinical AD after six months had greater ventricular enlargement than stable MCI subjects (P = 0.0270). Ventricular enlargement was different between Apolipoprotein E genotypes within the AD group (P = 0.010). The number of subjects required to demonstrate a 20% change in ventricular enlargement was substantially lower than that required to demonstrate a 20% change in cognitive scores. Ventricular enlargement represents a feasible short-term marker of disease progression in subjects with MCI and subjects with AD for multi-centre studies.Keywords
This publication has 43 references indexed in Scilit:
- Comparison of different MRI brain atrophy rate measures with clinical disease progression in ADNeurology, 2004
- Changes in premorbid brain volume predict Alzheimer’s disease pathologyNeurology, 2003
- MR-Volumetrie zur Darstellung von Verteilung und zeitlicher Abfolge neokortikaler Degeneration bei Morbus AlzheimerDer Radiologe, 2003
- Early diagnosis of alzheimer’s disease: contribution of structural neuroimagingNeuroImage, 2003
- Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypesNeurology, 2002
- Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change AnalysisNeuroImage, 2002
- Serial brain MRI at 3–6 month intervals as a surrogate marker for Alzheimer's diseaseThe British Journal of Radiology, 2002
- MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer’s disease and normal agingMagnetic Resonance Imaging, 2002
- The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation studyBMC Medical Research Methodology, 2001
- Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trialBMJ, 2000